share_log

Individual Investors Invested in Tinavi Medical Technologies Co.,Ltd. (SHSE:688277) Copped the Brunt of Last Week's CN¥674m Market Cap Decline

Individual Investors Invested in Tinavi Medical Technologies Co.,Ltd. (SHSE:688277) Copped the Brunt of Last Week's CN¥674m Market Cap Decline

個人投資者投資了天智醫療技術有限公司, Ltd.(上海證券交易所代碼:688277)首當其衝地應對了上週6.74億元人民幣市值下跌的衝擊
Simply Wall St ·  03/28 08:57

Key Insights

關鍵見解

  • Significant control over Tinavi Medical TechnologiesLtd by individual investors implies that the general public has more power to influence management and governance-related decisions
  • A total of 25 investors have a majority stake in the company with 47% ownership
  • Insider ownership in Tinavi Medical TechnologiesLtd is 19%
  • 個人投資者對Tinavi Medical TechnologiesLtd的嚴格控制意味着公衆擁有更大的影響管理和治理相關決策的權力
  • 共有25名投資者持有該公司的多數股權,所有權爲47%
  • Tinavi Medical TechnologiesLtd的內部所有權爲19%

If you want to know who really controls Tinavi Medical Technologies Co.,Ltd. (SHSE:688277), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 52% to be precise, is individual investors. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

如果你想知道誰真正控制了天智醫療技術有限公司, Ltd.(上海證券交易所代碼:688277),那麼你必須看看其股票登記處的構成。持有公司股份最多的集團是個人投資者,準確地說約爲52%。也就是說,如果股票上漲,該集團將受益最大(如果股價下跌,則損失最大)。

While insiders, who own 19% shares weren't spared from last week's CN¥674m market cap drop, individual investors as a group suffered the maximum losses

儘管擁有19%股票的內部人士未能倖免於上週6.74億元人民幣的市值下跌,但個人投資者作爲一個整體遭受的損失最大

Let's take a closer look to see what the different types of shareholders can tell us about Tinavi Medical TechnologiesLtd.

讓我們仔細看看不同類型的股東能告訴我們關於天航醫療科技有限公司的哪些信息。

ownership-breakdown
SHSE:688277 Ownership Breakdown March 28th 2024
SHSE: 688277 所有權明細 2024 年 3 月 28 日

What Does The Institutional Ownership Tell Us About Tinavi Medical TechnologiesLtd?

關於Tinavi Medical TechnologiesLtd,機構所有權告訴我們什麼?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

機構在向自己的投資者報告時通常會根據基準來衡量自己,因此,一旦股票被納入主要指數,他們通常會對股票更加熱情。我們預計大多數公司都會有一些機構在冊,尤其是在它們正在成長的情況下。

We can see that Tinavi Medical TechnologiesLtd does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Tinavi Medical TechnologiesLtd, (below). Of course, keep in mind that there are other factors to consider, too.

我們可以看到,Tinavi Medical TechnologiesLtd確實有機構投資者;他們持有該公司很大一部分股票。這意味着在這些機構工作的分析師已經看過這隻股票,他們很喜歡。但是就像其他人一樣,他們可能錯了。如果兩個大型機構投資者試圖同時拋售股票,股價大幅下跌的情況並不少見。因此,值得查看Tinavi Medical TechnologiesLtd過去的收益軌跡(見下文)。當然,請記住,還有其他因素需要考慮。

earnings-and-revenue-growth
SHSE:688277 Earnings and Revenue Growth March 28th 2024
SHSE: 688277 2024 年 3 月 28 日收益和收入增長

Hedge funds don't have many shares in Tinavi Medical TechnologiesLtd. The company's largest shareholder is Songgen Zhang, with ownership of 17%. Beijing Zhihui Hechuang Venture Capital Partnership Enterprise (Limited Partnership) is the second largest shareholder owning 7.4% of common stock, and Guotou China Merchant Investment Management Co., Ltd. holds about 5.3% of the company stock.

對沖基金在 Tinavi Medical TechnologiesLtd 中的股份不多。該公司的最大股東是張松根,所有權爲17%。北京智匯合創風險投資合夥企業(有限合夥)是第二大股東,擁有7.4%的普通股,國投中商投資管理有限公司持有公司約5.3%的股份。

On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest.

在研究我們的所有權數據時,我們發現25位大股東共同擁有的股份不到50%,這意味着沒有一個人擁有多數股權。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.

研究機構所有權是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒也可以達到同樣的目的。我們的信息表明,分析師對該股沒有任何報道,因此可能鮮爲人知。

Insider Ownership Of Tinavi Medical TechnologiesLtd

天航醫療科技有限公司的內部所有權

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

不同國家對內部人員的定義可能略有不同,但董事會成員總是計算在內。公司管理層經營業務,但首席執行官將向董事會負責,即使他或她是董事會成員。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲這可能表明董事會與其他股東關係良好。但是,在某些情況下,過多的權力集中在該群體中。

It seems insiders own a significant proportion of Tinavi Medical Technologies Co.,Ltd.. Insiders own CN¥771m worth of shares in the CN¥4.2b company. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.

內部人士似乎擁有天航醫療科技公司的很大一部分股份。,有限公司。內部人士擁有這家42億元人民幣公司價值7.71億元人民幣的股份。這可能表明創始人仍然擁有大量股份。你可以點擊這裏查看他們是否在買入或賣出。

General Public Ownership

一般公有制

The general public, who are usually individual investors, hold a substantial 52% stake in Tinavi Medical TechnologiesLtd, suggesting it is a fairly popular stock. With this amount of ownership, retail investors can collectively play a role in decisions that affect shareholder returns, such as dividend policies and the appointment of directors. They can also exercise the power to vote on acquisitions or mergers that may not improve profitability.

公衆通常是個人投資者,持有Tinavi Medical TechnologiesLtd52%的大量股份,這表明這是一隻相當受歡迎的股票。有了這麼多的所有權,散戶投資者可以在影響股東回報的決策中共同發揮作用,例如股息政策和董事任命。他們還可以對可能不會提高盈利能力的收購或合併行使投票權。

Private Equity Ownership

私募股權所有權

With a stake of 11%, private equity firms could influence the Tinavi Medical TechnologiesLtd board. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

私募股權公司持有11%的股份,可能會影響天航醫療科技有限公司的董事會。有時我們會看到私募股權長期存在,但總的來說,它們的投資期限較短,而且顧名思義,對上市公司的投資並不多。一段時間後,他們可能會考慮出售資本並將其重新部署到其他地方。

Private Company Ownership

私人公司所有權

Our data indicates that Private Companies hold 10%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

我們的數據表明,私人公司持有該公司10%的股份。私營公司可能是關聯方。有時,內部人士通過持有私營公司來對上市公司感興趣,而不是以個人身份感興趣。雖然很難得出任何粗略的結論,但值得注意的是,這是一個有待進一步研究的領域。

Next Steps:

後續步驟:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Be aware that Tinavi Medical TechnologiesLtd is showing 1 warning sign in our investment analysis , you should know about...

我覺得看看究竟誰擁有一家公司非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。請注意,Tinavi Medical TechnologiesLtd在我們的投資分析中顯示了1個警告信號,你應該知道...

Of course this may not be the best stock to buy. Therefore, you may wish to see our free collection of interesting prospects boasting favorable financials.

當然,這可能不是最值得買入的股票。因此,您可能希望看到我們免費收集的具有良好財務狀況的有趣潛在客戶。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論